LUCD实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 04:00):

Stats
今日成交量	300 346
平均成交量	220 903
市值	46.28M
EPS	$-0.250 ( 2024-03-26 )
下一个收益日期	( $-0.270 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.740
ATR14	$0.00400 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-07	Gordon Michael Adam	Buy	400 000	Common stock
2024-05-07	O'neil Shaun	Buy	400 000	Common stock
2024-05-07	Mcgrath Dennis M	Buy	400 000	Common stock
2024-05-07	Aklog Lishan	Buy	400 000	Common stock
2024-02-22	White Debra	Buy	150 000	Employee stock option (right to buy)

INSIDER POWER
43.00
Last 61 transactions
Buy: 14 783 319 \| Sell: 4 158 892

音量相关性

長: -0.02 (neutral)

短: 0.23 (neutral)

Signal:(45.831) Neutral

Lucid Diagnostics Inc. 相关性

10 最正相关
HCDIP	0.958
NLSP	0.954
HAIN	0.951
SIRI	0.945
NOVN	0.943
TRVN	0.942
PHCF	0.941
RMGC	0.937
TTEC	0.937
FRHC	0.936

10 最负相关
TRMR	-0.96
VITL	-0.951
THRN	-0.941
ARTEU	-0.94
GGAL	-0.939
DXPE	-0.937
RZLT	-0.935
CDXC	-0.935
GHRS	-0.934
IXAQ	-0.932

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Lucid Diagnostics Inc. 相关性 - 货币/商品

-0.50
( neutral )

0.40
( neutral )

0.00
( neutral )

0.48
( neutral )

Lucid Diagnostics Inc. 财务报表

Annual	2023
营收:	$2.43M
毛利润:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2023
营收:	$2.43M
毛利润:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2022
营收:	$377 000
毛利润:	$-3.24M (-858.62 %)
EPS:	$-1.550

FY	2021
营收:	$500 000
毛利润:	$-85 000.00 (-17.00 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

实时更新： Lucid Diagnostics Inc. [LUCD]

Upcoming Earnings Alert